Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.

Guo R, Schreyer M, Chang JC, Rothenberg SM, Henry D, Cotzia P, Kris MG, Rekhtman N, Young RJ, Hyman DM, Drilon A.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00021. Epub 2019 Jun 3. No abstract available.

2.

Selective RET kinase inhibition for patients with RET-altered cancers.

Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A.

Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.

3.

Targeting RET-rearranged non-small-cell lung cancer: future prospects.

Bronte G, Ulivi P, Verlicchi A, Cravero P, Delmonte A, Crinò L.

Lung Cancer (Auckl). 2019 Mar 20;10:27-36. doi: 10.2147/LCTT.S192830. eCollection 2019. Review.

4.

Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.

O'Leary C, Xu W, Pavlakis N, Richard D, O'Byrne K.

Cancers (Basel). 2019 May 3;11(5). pii: E620. doi: 10.3390/cancers11050620. Review.

5.

LOXO-292 Reins In RET-Driven Tumors.

[No authors listed]

Cancer Discov. 2018 Aug;8(8):904-905. doi: 10.1158/2159-8290.CD-NB2018-070. Epub 2018 Jun 2.

6.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA.

Cancer Discov. 2015 Oct;5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27.

7.

RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.

Sarfaty M, Moore A, Neiman V, Dudnik E, Ilouze M, Gottfried M, Katznelson R, Nechushtan H, Sorotsky HG, Paz K, Katz A, Saute M, Wolner M, Moskovitz M, Miller V, Elvin J, Lipson D, Ali S, Gutman LS, Dvir A, Gordon N, Peled N.

Clin Lung Cancer. 2017 Jul;18(4):e223-e232. doi: 10.1016/j.cllc.2016.09.003. Epub 2016 Oct 29.

PMID:
28082048
8.

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV.

Lung Cancer. 2015 Jul;89(1):76-9. doi: 10.1016/j.lungcan.2015.04.004. Epub 2015 Apr 22.

9.

RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.

Wang Y, Xu Y, Wang X, Sun C, Guo Y, Shao G, Yang Z, Qiu S, Ma K.

Medicine (Baltimore). 2019 Jan;98(3):e14120. doi: 10.1097/MD.0000000000014120.

10.

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.

Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, Mao M, Han J, Kim J, Choi YL.

Mod Pathol. 2015 Apr;28(4):468-79. doi: 10.1038/modpathol.2014.107. Epub 2014 Sep 19.

11.

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.

Arai S, Kita K, Tanimoto A, Takeuchi S, Fukuda K, Sato H, Yano S.

Oncotarget. 2017 May 16;8(43):73766-73773. doi: 10.18632/oncotarget.17900. eCollection 2017 Sep 26.

12.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N.

Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.

13.

KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.

Qian Y, Chai S, Liang Z, Wang Y, Zhou Y, Xu X, Zhang C, Zhang M, Si J, Huang F, Huang Z, Hong W, Wang K.

Mol Cancer. 2014 Jul 21;13:176. doi: 10.1186/1476-4598-13-176.

14.

Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.

Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S.

J Med Invest. 2017;64(3.4):317-320. doi: 10.2152/jmi.64.317.

15.

Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.

Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, Sakatani T, Oguni S, Tamura T, Kataoka H, Endo S, Murakami Y, Aburatani H, Fukayama M, Niki T.

J Thorac Oncol. 2012 Dec;7(12):1872-1876. doi: 10.1097/JTO.0b013e3182721ed1.

16.

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.

Gozgit JM, Chen TH, Song Y, Wardwell S, Wang F, Cai J, Li H, Edgren H, Rivera VM, Pritchard J.

Oncotarget. 2018 Jul 3;9(51):29654-29664. doi: 10.18632/oncotarget.25664. eCollection 2018 Jul 3.

17.

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.

Furugaki K, Mochizuki M, Kohno M, Shu S, Harada N, Yoshimura Y.

BMC Cancer. 2019 Apr 3;19(1):301. doi: 10.1186/s12885-019-5527-2.

18.

Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing.

Zhang X, Li Y, Liu C, Wang W, Li M, Lv D, Sun G, Chen H, Dong X, Miao Z, Yao M, Wang K, Tian H.

Lung Cancer. 2018 Apr;118:27-29. doi: 10.1016/j.lungcan.2017.08.019. Epub 2017 Sep 4.

PMID:
29571998
19.

Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.

Lee MS, Kim RN, I H, Oh DY, Song JY, Noh KW, Kim YJ, Yang JW, Lira ME, Lee CH, Lee MK, Kim YD, Mao M, Han J, Kim J, Choi YL.

Oncotarget. 2016 Jun 14;7(24):36101-36114. doi: 10.18632/oncotarget.9137.

20.

KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.

Yokota K, Sasaki H, Okuda K, Shimizu S, Shitara M, Hikosaka Y, Moriyama S, Yano M, Fujii Y.

Oncol Rep. 2012 Oct;28(4):1187-92. doi: 10.3892/or.2012.1908. Epub 2012 Jul 13.

PMID:
22797671

Supplemental Content

Support Center